Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
A phase I study of frequently administered carboplatin with recombinant human granulocyte colony-stimulating factor (filgrastim) has been performed in patients with newly diagnosed epithelial ovarian cancer. Recombinant human granulocyte colony-stimulating factor was administered at a dose of 5 micrograms/kg/d for days 1 through 12 after carboplatin treatment. Carboplatin doses were calculated using a pharmacokinetic formula on an area under the curve (AUC) basis. Four doses of carboplatin were planned for each patient. The first cohort of patients received an AUC of 5 mg/mL x min every 3 weeks. Subsequently four additional cohorts received AUCs of 5, 7, 9, and 8 every 2 weeks. Non-hematologic toxicities were mild and not significant. The dose-limiting toxicity was thrombocytopenia and occurred at an AUC of 9. Most patients could complete treatment at an AUC of 7. Results for AUC 8 are awaited. Complete and partial responses were seen in most patients at all dose levels.
Author(s): Calvert, A. H., Lind, M. J., Ghazalaswad, S., Gumbrell, L., Millward, M. J., Bailey, N. P. , Doregreen, F., Chapman, F., Simmons, D., Proctor, M., Oakey, A., Sinha, D. P., McCann, E., Middleton, I.
Publication type: Article
Publication status: Published
Journal: Seminars in Oncology
Year: 1994
Volume: 21
Issue: 5 Supplement 12
Pages: 1-6
Print publication date: 01/10/1994
ISSN (print): 0093-7754
ISSN (electronic): 1532-8708
PubMed id: 7527590
